Evidence map›Paper›PMID 34295845›Full record

ReviewResearch and reports in urology2021

Emerging Data on the Safety and Efficacy of Transurethral Water Vapour Therapy for Benign Prostatic Hyperplasia.

Patrick Jones, Giampaolo Siena, B M Zeeshan Hameed, Bhaskar K Somani

Open access · goldAbstract readReview
In one paragraph

Review in Research and reports in urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Small procedures, big complications.World journal of urology · 2026
    Article
  2. Article
  3. Efficacy of Rezūm water vapor therapy for the treatment of catheter-dependent urinary retention A single-center, Canadian experience.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 5 countries.

Patrick JonesDepartment of Urology, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0003-4253-1283
Giampaolo SienaDepartment of Urology, Careggi University Hospital, Florence, Italy.
B M Zeeshan HameedEAU Young Academic Urology Urolithiasis and Endourology Working Party, Arnhem, Netherlands.
Bhaskar K SomaniEAU Young Academic Urology Urolithiasis and Endourology Working Party, Arnhem, Netherlands.ORCID 0000-0002-6248-6478
Azienda Ospedaliero-Universitaria Careggi · ITEuropean Association of Urology · NLHaukeland University Hospital · NOManipal Academy of Higher Education · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign prostate disease is a disease of prevalence and over 25% of men affected by bothersome lower urinary tract symptoms (LUTS) as a result of it will require surgical intervention during their lifetime. While transurethral resection of the prostate (TURP) has served as the cornerstone treatment for many years, there now exist a multitude of minimally invasive alternatives including the Rezum system. The latter is a novel form of transurethral water vapour therapy, which is attracting increasing attention. It utilizes convective water vapour energy (WAVE) and thereby radiofrequency (RF) in order to generate heat energy. Early studies have demonstrated promising results. To date there have been 12 studies published on Rezum, however only one randomized trial. This review offers an overview and evaluation of this emerging evidence.

Indexed as

benign prostatic hyperplasiaBPHminimally invasive surgeryprostateRezum

Identifiers

PMID34295845
PMCPMC8290348
OpenAlexW3163399895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.